Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction

Prescribers should consider reducing the dose of ponatinib to 15 mg a day for patients with chronic phase chronic myeloid leukaemia (CP-CML) who have achieved a major cytogenetic response.